Understanding HIV compartments and reservoirs

Current HIV/AIDS Reports

Volumn 11, Issue 2, 2014, Pages 186-194

  Svicher, Valentina ^a   Ceccherini Silberstein, Francesca ^a   Antinori, Andrea ^b   Aquaro, Stefano ^c   Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Anatomical compartment; Anatomical sanctuary; Breast; Central nervous system; Drug penetration; Global; Gut; HIV; HIV 1; HIV 1 infection; HIV AIDS; Infection; Lymph nodes; Macrophages; Memory T cells; Reservoirs; Semen

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

APOPTOSIS; ARTICLE; ASTROCYTE; BREAST; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DISEASE CARRIER; DRUG PENETRATION; GASTROINTESTINAL MUCOSA; GENE; GENETIC VARIABILITY; GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER; LYMPH NODE; NONHUMAN; PATHOGENESIS; STOMACH MUCOSA; VIRION; VIRUS INHIBITION; VIRUS REPLICATION; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; PATHOGENICITY; STATISTICS AND NUMERICAL DATA; VIREMIA; VIROLOGY; VIRUS LATENCY; VIRUS LOAD;

ANTI-HIV AGENTS; BREAST; CENTRAL NERVOUS SYSTEM; DISEASE RESERVOIRS; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; GENITALIA; HIV INFECTIONS; HIV-1; HUMANS; LIVER; LYMPH NODES; MALE; VIRAL LOAD; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84903617940     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0207-y     Document Type: Article

References (94)

1. .•• Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377-88. This perspective proposes definitions for key terms in the field of HIV-1 latency, reservoirs and eradication. This paper represents a starting point for refining the terminology in cure research.
2. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68:1169-78.
3. •• Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211. This paper showed that early and prolonged antiretroviral treatment can reduce the burden of HIV-1 cellular reservoirs in some patients including those with an unfavorable genetic profile in controlling HIV infection. This paper highlights that an early treatment may represent a strategy aimed at achieving functional HIV cure.
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512 - 7.
5. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
6. Buzon M, Sun H, Li C, Martin-Gayo E, et al. T Memory Stem Cells Are a Long-term Reservoir for HIV1. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA (USA); March 3-6, 2013.
7. Gattinoni L, Lugli E, Ji Y, et al.A humanmemory Tcell subset with stem cell-like properties. Nat Med. 2011;17:1290-7.
8. Zhong P, Agosto LM, Ilinskaya A, et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One. 2013;8:e53138.
9. Abela IA, Berlinger L, Schanz M, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 2012;8:e1002634.
10. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011;17:95-8.
11. .•• Duncan CJ, Russell RA, Sattentau QJ. Highmultiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS. 2013;27:2201-6. This interesting study shows that cell-to-cell HIV-1 transmission from macrophages to CD4+T cells can reduce the efficacy of several antiretroviral agents belonging to different drug classes compared to cell-free transmission. The authors pointed out that this difference is not qualitative but quantitative, and thus can be explained by the high quantity of viral particles transmitted through virological synapses.
12. Cohen J. HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 2011, 334:1614.
13. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol. 1999;73:9741 - 55.
14. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ Tcell depletion and viral replication in SIV infection. Science. 1998;280:427-31. (Pubitemid 28208163)
15. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-70. (Pubitemid 39299462)
16. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-59. (Pubitemid 39299461)
17. .•• Swanstrom R, Coffin J. HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med. 2012;2. This review provides a detailed description of mechanisms underlying HIV pathogenesis in different anatomical compartments.
18. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(R) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869-73. (Pubitemid 28350581)
19. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008;105:16725- 30.
20. Centlivre M, Sommer P, Michel M, et al. The HIV-1 clade C promoter is particularly well adapted to replication in the gut in primary infection. AIDS. 2006;20:657-66. (Pubitemid 43884292)
21. .• Yukl SA, Shergill AK, Ho T, et al.: The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence. J Infect Dis. 2013. doi: 10.1093/infdis/jit308. This interesting paper pointed out that the pool of cellular HIV-1 reservoirs in the gut may be different from that observed in peripheral blood, and highlighted the existence of non-CD4(+) T leukocytes as a new potential target of HIV infection. These results are important in order to set up effective therapeutic strategies aimed at achieving HIV cure.
22. .• McElrath MJ, Smythe K, Randolph-Habecker J, et al. on behalf of NIAID HIV Vaccine Trials Network: Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J Acquir Immune Defic Syndr. 2013;63:263-71. This study highlights a different distribution of macrophages between the colum and the rectum suggesting that these 2 gut tracts could act as distinct anatomical compartments.
23. Avettand-Fenoel V, Hocqueloux L, Müller-Trutwin M, et al. Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART. J Med Virol. 2011;83:1499-507.
24. .• Imamichi H, Degray G, Dewar RL, et al. Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis. 2011;204:309-14. This study provides evidence for the lack of compartimentalization between the gastrointestinal tract and peripheral blood. It suggests a free exchange of virions or infected cells between the 2 anatomical sites.
25. .•• Evering TH, Mehandru S, Racz P, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012;8:e1002506. This study suggests that initiation of antiretroviral therapy during acute/early HIV-1 infection can result in the interruption of measurable viral evolution in the gut-associated lymphoids tissues, suggesting the absence of de-novo rounds of HIV-1 replication in this compartment during suppressive therapy.
26. Katzenstein TL, Petersen AB, Storgaard M, et al. Phylogeny and resistance profiles of HIV-1 POL sequences from rectal biopsies and blood. J Med Virol. 2010;82:1103-9.
27. van Marle G, Gill MJ, Kolodka D, et al. Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology. 2007;4:87.
28. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-termantiretroviral therapy. J Infect Dis. 2008;197:714-20. (Pubitemid 351364472)
29. Lafeuillade A, Cheret A, Hittinger G, et al. Rectal cell-associated HIV-1 RNA: a new marker ready for the clinic. HIV Clin Trials. 2009;10:324-7.
30. Liu R, Huang L, Li J, et al. HIV Infection in Gastric Epithelial Cells. J Infect Dis. 2013. doi: 10.1093/infdis/jit314.
31. Blackard JT, Ma G, Martin CM, et al. HIV variability in the liver and evidence of possible compartmentalization. AIDS Res Hum Retroviruses. 2011;27:1117-26.
32. Bruno R, Galastri S, Sacchi P, et al.: gp120 modulates the biology of human hepatic stellate cells: a link between HIVinfection and liver fibrogenesis. Gut 2010, 59:513-520.
33. Kaul M, Garden G, Lipton S. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988-94. (Pubitemid 32335850)
34. Garaci E, Caroleo MC, Aloe L, et al. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A. 1999;96:14013-8.
35. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798-812.
36. Cassol E, Alfano M, Biswas P, et al. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006;80:1018-130.
37. Aquaro S, Bagnarelli P, Guenci T, et al. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol. 2002;68:479-88. (Pubitemid 35231773)
38. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology. 2012;9:82.
39. Orenstein J, Fox C,Wahl S.Macrophages as a source of HIV during opportunistic infections. Science. 1997;276:1857-61.
40. Swingler S, Mann A, Jacqué J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med. 1999;5:997-1103.
41. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci. 2002;25:537-362.
42. Le Douce V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology. 2010;7:32.
43. Hauser KF, Fitting S, Dever SM, et al. Opiate drug use and the pathophysiology of neuro AIDS. Curr HIV Res. 2012;10:435-52.
44. Zhang D, Hu X, Qian L, et al. Astrogliosis in CNS pathologies: is there a role for Microglia? Mol Neurobiol. 2010;41:232-41.
45. Muscoli C, Salvemini D, Paolino D, et al. Peroxynitrite decomposition catalyst prevents apoptotic cell death in a human astrocytoma cell line incubated with supernatants of HIV-infected macrophages. BMC Neurosci. 2002;3:13.
46. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003;27:325-55. (Pubitemid 38156291)
47. Peng H, Sun L, Jia B, et al. HIV-1-infected and immune-activated macrophages induce astrocytic differentiation of human cortical neural progenitor cells via the STAT3 pathway. PloS One. 2011;6:e19439.
48. Aquaro S, Panti S, Caroleo MC, et al. Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J Leukoc Biol. 2000;68:429-35.
49. Narasipura SD, Henderson LJ, Fu SW, et al. Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes. J Virol. 2012;86:1911-21.
50. Eugenin EA, Berman JW: Cytochrome C dysregulation induced by HIV infection of astrocytes results in bystander apoptosis of uninfected astrocytes by an IP(3) and Calcium dependent mechanism. J Neurochem. 2013. doi: 10.1111/jnc.12443.
51. Strain MC, Letendre S, Pillai SK, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol. 2005;79:1772-88. (Pubitemid 40459123)
52. Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009;23:907-15.
53. Schnell G, Spudich S, Harrington P, et al. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 2009;5:e1000395.
54. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic distance between plasma and CSF in patients with neurological disorders. International HIV and Hepatitis Drug Resistance Workshop. June 8-12, 2010. Dubrovnik, Croatia. Abstract 127.
55. Nowacek A, Gendelman H. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine. 2009;4:557-74.
56. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
57. Letendre S, Marquie-Beck J. Validation of the CNS penetration- effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
58. Marra C, Zhao Y, Clifford D, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-66.
59. Smurzynski M, Wu K, Letendre S, et al. Effect of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357-65.
60. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416-23. (Pubitemid 39166561)
61. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother. 2010;20:63-78.
62. Langford D, Marquie-Beck J, de Almeida S, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol. 2006;12:100-7. (Pubitemid 44574601)
63. Smit TK, Brew BJ, Tourtellotte W, et al. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004;78:10133-48. (Pubitemid 39187131)
64. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194:1686-96. (Pubitemid 44901999)
65. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773-8.
66. Kelly KM, Beck SE, Pate KA, et al. Neuroprotective maraviroc monotherapy in SIV-infected macaques: reduced replicating and latent SIV in the brain. AIDS 2013. Epub ahead of print.
67. Borgmann K, Rao K, Labhasetwar V, Ghorpade A. Efficacy of Tatconjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses. 2011;27:853-62.
68. Gratton S, Cheynier R, Dumaurier MJ, et al. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A. 2000;97:14566-71. (Pubitemid 32016616)
69. Spiegel H, Herbst H, Niedobitek G, et al. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol. 1992;140:15-22.
70. Burton GF, Keele BF, Estes JD, et al. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol. 2002;14:275-84. (Pubitemid 34969896)
71. Horiike M, Iwami S, Kodama M, et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology. 2012;423:107-18.
72. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921.
73. Butler DM, Smith DM, Cachay ER, et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS. 2008;22:1667-71.
74. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29.
75. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-404.
76. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25:473-7.
77. Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS. 2008;22:1677-9.
78. Sheth PM, Kovacs C, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS. 2009;23:2047-59.
79. Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS. 2012;26:1535-43.
80. Halfon P, Giorgetti C,Khiri H, et al. Semenmay harbor HIVdespite effective HAART: another piece in the puzzle. PLoS One. 2010;5:e10569.
81. .•• Gianella S, Smith DM, Vargas MV, et al. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1- infected men who have sex with men. Clin Infect Dis. 2013;57: 441-7. This study highlights a correlation between the presence of some herpesviruses and HIV-1 shedding in semen despite undetectable viremia, thus conferring a potential risk of HIV-1 transmission.
82. Craigo JK, Gupta P. HIV-1 in genital compartments: vexing viral reservoirs. Curr Opin HIVAIDS. 2006;1:97-102.
83. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIVAIDS. 2010;5:335-43.
84. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149-67.
85. Sheth PM, Yi TJ, Kovacs C, et al. Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy. Mucosal Immunol. 2012;5:248-57.
86. Anderson JA, Ping LH, Dibben O, et al. HIV-1 Populations in semen arise through multiple mechanisms. PLoS Pathog. 2010;6: e1001053.
87. Gianella S, Morris SR, Vargas MV, et al. Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis. 2013;207:257-61.
88. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
89. Cates Jr W. After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet. 2010;376:495-6.
90. Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe. 2011;10:379-89.
91. •• Introini A, Vanpouille C, Lisco A, Grivel JC, Margolis L. Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog. 2013, e1003148. This interesting study highlights the IL-7 capability in promoting HIV-1 replication in cervico-vaginal tissue. This has strong implication in sexual transmission of HIV-1 infection.
92. Antoniou T, Hasan S, Loutfy MR, et al. Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men. J Acquir Immune Defic Syndr. 2013;62:e58-60.
93. Petitjean G, Becquart P, Tuaillon E, et al. Isolation and characterization of HIV-1-infected resting CD4+ T lymphocytes in breast milk. J Clin Virol. 2007;39:1-8. (Pubitemid 46584830)
94. Becquet R, Ekouevi DK, Arrivé E, et al. Universal antiretroviral therapy for pregnant and breastfeeding HIV-1-infected women: Towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis. 2009;49:1936-45.